Terms of Use
This website is owned and operated by Cerevance, LLC, a limited liability company with a business address of One Marina Park Drive, Suite 1410, Boston, MA 02210, United States, and its subsidiaries (collectively “Cerevance”, “we”, or “us”).
These Terms of Use refer to the current website you are visiting (the “Website”). All access to and use of this Website is governed by these Terms of Use. Visiting and using this Website indicates that the user (either “user” or “you” in this document) has reviewed these Terms of Use and has agreed to be bound by them as well as our Privacy Policy. The information provided on our Website is for informational purposes only. If you do not agree to these Cerevance Terms ofUse and Privacy Policy, you may not use or access this Website and are requested to leave the Website immediately.
Disclaimer
This Website contains general information regarding Cerevance products and operations. This information is not intended to provide medical advice. You should always consult a physician or other qualified health professional for medical advice and treatment. If you think you may have a medical emergency, call your doctor, 911 (in the US), or 112 (in the European Union (EU))immediately.
All information on this Website is subject to change without notice. While efforts have been made to make this Website helpful and accurate, Cerevance does not warrant the accuracy of information obtained from this Website. Where errors or omissions are brought to the attention of Cerevance, amendments will be made as speedily as possible.
ALL MATERIALS POSTED ON THIS WEBSITE ARE PROVIDED “AS IS” AND WITHOUT WARRANTIES EXPRESS OR IMPLIED. CEREVANCE AND ITS AGENTS AND THE WEBSITE CREATORS DISCLAIM TO THE FULLEST EXTENT PERMISSIBLE BY APPLICABLE LAW, ALL WARRANTIES INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. CEREVANCE DOES NOT WARRANT THAT FUNCTIONS CONTAINED ON THIS WEBSITE WILL BE UNINTERRUPTED OR ERROR-FREE, THAT DEFECTS WILL OR CAN BE CORRECTED, OR THAT THIS WEBSITE OR THE SERVER ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. CEREVANCE DOES NOT PROVIDE ANY WARRANTY OR REPRESENTATION AS TO THE MATERIALS ON THIS WEBSITE IN TERMS OF THEIR CORRECTNESS, ACCURACY, RELIABILITY, OR OTHERWISE.
Scope of Use
Cerevance provides this Website for informational and educational purposes, and for the general interest of its users. Your access to and use of the information contained in this Website is subject to these Terms of Use; by accessing and using this Website, you accept, without limitation or qualification, these Terms of Use. Cerevance invites you to view and use this Website for your informational, non-commercial use. Except as otherwise provided on this page, no part of any content of thisWebsite may be copied, downloaded, or stored in a retrieval system for any other purpose, nor may it be redistributed for any purpose, without the expressed written permission of Cerevance.
Access to the Website is limited to viewing the linked webpages solely for information purposes to access the information provided by Cerevance at this Website. Any access or attempt to access other areas of Cerevance’s computer system or other information contained on the system for any purposes is strictly prohibited.
Content
The content featured on this Website is intended to be a general information resource to provide you with a variety of information, including information about Cerevance clinical research, products, and information relating to diseases of the central nervous system. This information is not intended to provide, and does not constitute, medical advice, decision making, recommendations, or direction in any way. You should always consult with a physician or other qualified health professional for medical advice and treatment.
Limitation of Liability
IN NO EVENT WILL CEREVANCE, ITS AGENTS, OR THE WEBSITE CREATORS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, SPECIAL AND CONSEQUENTIAL DAMAGES, LOSSOR LIABILITY WHATSOEVER (INCLUDING, WITHOUT LIMITATION, THOSE RESULTING FROM LOST PROFITS, LOST DATA OR BUSINESS INTERRUPTION) ARISING OUT OF THE USE,INABILITY TO USE, OR THE RESULTS OF USE OF OR RELIANCE ON THIS WEBSITE OR ACCESS TO ANY MATERIALS ON THE WEBSITE, ANY WEBSITES LINKED TO THIS WEBSITE, ORTHE MATERIALS OR INFORMATION CONTAINED AT ANY OR ALL SUCH SITES, OR ANY FAILURE OF PERFORMANCE, ERROR, OMISSION, INTERRUPTION, DEFECT, DELAY IN TRANSMISSION,COMPUTER VIRUS OR TELECOMMUNICATIONS FAILURE OF THIS WEBSITE WHETHER BASED ON WARRANTY, CONTRACT, TORT OR ANY OTHER LEGAL THEORY AND WHETHER OR NOT ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND EVEN IF SUCH LOSS OR DAMAGE IS CAUSED BYTHE NEGLIGENCE OF THE COMPANY OR ITS AGENTS. IF YOUR USE OF THE MATERIALS OR INFORMATION FROM THIS WEBSITE RESULTS IN THE NEED FOR SERVICING, REPAIR, OR CORRECTION OF EQUIPMENT OR DATA, YOU ASSUME ALL COSTS THEREOF. APPLICABLE LAW MAY NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATION OR EXCLUSION MAY NOT APPLY TO YOU.
IN ADDITION, THE COMPANY SHALL NOT HAVE ANY LIABILITY TO ANY PERSON FOR ANY IN JURY OR LOSS (INCLUDING PERSONAL INJURY AND CONSEQUENTIAL LOSS) SUFFERED WHILE PARTICIPATING IN ANY TREATMENTS DESCRIBED OR REFERRED TO IN THE WEBSITE. THE MATERIAL IN THE WEBSITE IS GIVEN AS GENERAL INFORMATION ONLY AND THE COMPANY GIVES NO WARRANTY AS TO THE SAFETY AND SECURITY OF SUCH TREATMENTS.
Indemnification
You agree to defend, indemnify, and hold harmless Cerevance, its officers, directors, employees, agents, and licensees from any and all liability, including costs, expenses, and attorneys’ fees, resulting from any violation by you of these Terms of Use.
Privacy Policy
Cerevance respects the privacy of its Website users. Please refer to our Privacy Policy, which will inform you about our practices regarding collection, use, and disclosure of information, include personal data, that you may provide to Cerevance through this Website. The Privacy Policy may change from time to time.
E-mails Submitted to Cerevance
E-mail or other submissions over the Internet may not be private or secure. Please consider this before e-mailing any personal or confidential information to Cerevance or any affiliate. Cerevance cannot take any responsibility for information transmitted via the Website and cannot guarantee that any electronic commerce or communication is totally secure.
Submissions
We welcome submissions to this Website in the form of questions, requests, user information, and other. If you submit information to Cerevance through this Website (e.g., the “Contact Us” webpage, via email, forms and/or questionnaires), all such information may be processed and utilized by Cerevance in accordance with the Privacy Policy and consistent with applicable laws and regulations. Cerevance shall have all appropriate use for the information without compensation to the user or visitor who provided the information. You agree that you are responsible for all submissions that you provide and you, not Cerevance, shall have full responsibility of their
Information, News, and Press Releases
This Website contains information, news, and press releases about Cerevance. While this information was believed to be accurate as of the date it was prepared, Cerevance disclaims any duty or obligation to update this information, news, or any press releases. Information about companies other than Cerevance contained in the news, press releases, or otherwise, should not be relied upon as being provided or endorsed by Cerevance.
Updates
Certain webpages and sections of the Website are required to be updated periodically or as soon as new relevant information becomes available. These sections may be marked with the date tag or a caption/label. Date tags will also be updated if after periodic review, the pages are still deemed to be current. Changes that are administrative in nature (for example, section reference updates or grammatical improvements) may not have a date tag update.
Links
As a convenience, this Website may contain links to other company websites that are maintained and operated by those third parties. Such linked sites are not under the control of Cerevance, and Cerevance is not responsible for the content available on any other sites linked to this Website. Further, such links do not imply Cerevance’s endorsement, sponsorship, or recommendation of material on any other site, and Cerevance disclaims any warranties (expressed or implied) about the content and operation of those sites. Cerevance also disclaims any liability for links: (i) from another website to the Website, and (ii) to another website from the Website.
Cookie Policy
When you visit our Website and have accepted our cookies policy, we (and our service providers) may use cookies (small data files stored on your computer and used to provide you with a more personal, interactive experience) to automatically collect the following information:
- Technical information, including your IP address, browser type and version, device identifier, location and time zone setting, browser plug-in types and versions, operating system and platform, page response times and download errors.
- Information about your visit, including how you were directed to our Website.
- Length of visits to certain pages, page interaction information (such as scrolling, clicks and mouse movements), and methods used to browse away from the page.
Among the different types, we may use session cookies (which expire after you close your web browser), persistent cookies (which stay on your computer until you delete them), or other automatic data collection technologies. Cookies allow us to collect technical information such as browser type, time spent viewing our Website, webpages visited, language preferences, and other anonymous web traffic data and statistical information. We and our service providers also use the information for security purposes, to facilitate navigation, to display information more effectively, and to personalize your experience. Cookies further allow us to select which of our promotional content or offers are most likely to appeal to you, and we may display them while you navigate our Website. Some of the information we gather through cookies may be considered personal information in that we may view your online activities over time and across third-party websites (sometimes referred to as behavioral tracking).
If you do not want information collected through such cookies, you may opt out or decline to accept our cookies policy (you may also erase cookies from particular websites through your browser settings). There are some limited types of essential cookies that are required for appropriate Website operations on your device or computer, which cannot be declined. Also, if you do not accept cookies, it is possible that you may experience some inconvenience when using our Website in terms of design, efficiency, and your individual preferences.
Modifications
Cerevance reserves the right to modify or amend its Terms of Use at any time. Cerevance will endeavor to post changes to the Terms of Use on the Website when necessary and appropriate, and will provide an updated “Last Updated” date in the introduction above. Please check the Website regularly for the latest version of the Terms of Use.
Intellectual Property
This Website may contain trademarks and service marks. All marks are the property of the proprietors of such marks as indicated unless otherwise provided. All rights in the intellectual property contained in this Website including copyright, trademarks, trade secret, and patent rights are reserved. The editorial content of this Website and all text, graphics, logos, icons, images, audio clips and software is copyright of Cerevance and/or the authors, photographers and illustrators who contribute material to the Website, and the user shall not alter or remove any copyright symbol, or any other identification or information, concerning the authorship or ownership of any of the content of the Website. Access to this Website does not constitute a right to copy or use any of the intellectual property of Cerevance or its suppliers, and users are not permitted to copy, market, resell, distribute, retransmit, publish, upload, download, store, display in public, alter, or modify the content contained on this Website or otherwise transfer or commercially exploit, in any form, any of the content of the Website.
Minors
If you are aged 18 or under, please obtain your parent’s/guardian’s permission before you provide any personal information to us through this Website. Users without this consent are not allowed to provide us with personal information.
Cerevance complies with regulatory standards and requirements in all applicable countries and territories, and will only market and promote our products (once approved for sale/distribution) to approved patient groups. Under no circumstances, however, will Cerevance knowingly market, promote, or recommend any products or services to any persons under the age of 13, nor will we knowingly collect any personal information from persons under 13. If you are under the age of 13, please immediately stop using this Website and speak to your parent or guardian about obtaining information regarding Cerevance products and services.
Violations
Cerevance reserves the right to seek all remedies available at law and in equity for violations these Terms of Use, including the right to block access from a particular Internet address to the Website.
Use of Information
Cerevance reserves the right, and you authorize Cerevance, to use all information regarding your use of this Website and all information provided by you in any manner consistent with our Privacy Policy.
Governing Laws
Cerevance makes no representation that the information on its Website is appropriate or available for use in other locations, and access to the Website from territories where the content of its Website may be illegal is prohibited. Those who choose to visit the Website from other locations do so on their own initiative and are responsible for compliance with applicable local laws. These Terms of Use and the resolution of any dispute related to them or to the use of this Website, shall be governed by and construed in accordance with the laws of the United States, and shall be subject to the exclusive jurisdiction of the US courts. This will not prevent Cerevance from pursuing a claim for breach of contract, copyright infringement, or otherwise in respect of these Terms of Use in any other jurisdiction throughout the world.
How to Contact Us
If you have any questions about the Terms of Use (or the Privacy Policy), please contact us through our Contact Us webpage, or by mailing a letter to:
Cerevance, LLC
One Marina Park Drive, Suite 1410
Boston, MA 02210 USA
Attention: Legal Department
Current
November 18, 2024
Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease
- Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s disease
- ARISE will evaluate the efficacy of solengepras as an adjunctive therapy to levodopa and other background Parkinson’s disease medications
- Company expects to report topline data in the first half of 2026
November 11, 2024
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
- CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosing
- Dose-dependent exposure was observed with evidence of robust brain penetration
- Data supports potential advancement into Phase 2 for neurodegenerative diseases characterized by neuroinflammation such as Frontotemporal Dementia, AmyotrophicLateral Sclerosis, and Alzheimer’s Disease
October 21, 2024
Cerevance Announces Publication of Positive Phase 2 Results of Solengepras for the Treatment of Parkinson’s Disease in eClinical Medicine
Cerevance has published the full results from the Phase 2 clinical trial of solengepras, in eClinicalMedicine, a peer-reviewed journal published by The Lancet Discovery Science Suite. The results demonstrated that solengepras, a potentially first-in-class, oral, once-daily, non-dopaminergic, GPR6 inverse agonist, significantly reduced OFF time in individuals with Parkinson’s disease and was generally well-tolerated.
October 17, 2024
Sarah Sheikh Joins Cerevance’s Board of Directors
Cerevance is pleased to appoint Sarah Isabel Sheikh, M.Sc., B.M. B.Ch., MRCP, to its Board of Directors, effective immediately. Dr. Sheikh holds dual responsibilities at Takeda as the Head of Global Development for all therapeutic areas – Gastrointestinal and Inflammation, Neuroscience, Oncology, Plasma-Derived Therapies, and Vaccines – and as the Head of the Neuroscience Therapeutic Area.
October 8, 2024
Cerevance Achieves Second Milestone in Research Collaboration with Merck
Cerevance announced the achievement of the second milestone in its research collaboration with Merck, known as MSD outside of the United States and Canada. The research collaboration, which was announced in August of 2022, focuses on the identification and validation of novel therapeutic targets for Alzheimer’s disease. The achievement of this milestone triggers a payment from Merck to Cerevance.
August 12, 2024
Cerevance Appoints Sagar Vaidya, M.D., Ph.D., as Chief Medical Officer
Cerevance has appointed Dr. Sagar Vaidya, M.D., Ph.D., as Chief Medical Officer. Dr. Vaidya brings a wealth of experience in drug development, clinical research, and medical affairs, with a distinguished track record in advancing therapeutic programs for severe and life-threatening diseases.
May 2, 2024
Cerevance Achieves First Milestone in Research Collaboration with Merck
Cerevance achieves first milestone in research collaboration with Merck, known as MSD outside of the United States and Canada. The research collaboration, which was announced in August of 2022, focuses on the identification of novel therapeutic targets for Alzheimer’s disease. The achievement of this milestone triggers an undisclosed payment from Merck to Cerevance.
April 25, 2024
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
Cerevance announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised bringing the total Series B-1 raise to $98 million.
April 22, 2024
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
Cerevance announces that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.
February 15, 2024
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters. In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist”
November 13, 2023
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
September 19, 2023
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.
August 28, 2023
Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023
Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.
July 10, 2023
Cerevance to Present at the Alzheimers Association International Conference
Cerevance to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.
May 16, 2023
Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
Cerevance to present an oral presentation at the upcomingAmerican Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.
May 9, 2023
Cerevance to Present at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development
Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the NextGeneration of Therapeutic Development conference, taking place in British Columbia, Canada, May 15 – 19, 2023.
April 13, 2023
Poster Presentation at the BNA International Festival of Neuroscience
Cerevance today announced a poster presentation at the British Neuroscience Association (BNA) 2023 International Festival of Neuroscience in Brighton, United Kingdom being held April 23-26, 2023
March 21, 2023
Cerevance to Present at Two Medicinal Chemistry Conferences
Cerevance to present at two upcoming medicinal chemistry conferences:
- 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets held March 27-28 in Cambridge, UK
- Binding Kinetics and Mechanistic PK/PD Modeling in Early Drug Discovery Conference held March 27-28 in Cambridge, UK
March 20, 2023
Cerevance to Present at AD/PD™ 2023 International Conference
- Positive CVN424 Phase 2 data for Parkinson’s disease to be presented
- Presentation of NETSseq platform’s ability to reveal novel targets to inform CNS drug development
- Novel target, CVN417, for the potential treatment of Parkinson’s disease to be disclosed
February 13, 2023
Cerevance Expands Series B Financing with Additional $51 Million
- Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform
- CVN424 for Parkinson’s disease will advance to Phase 2 monotherapy study in Q2 2023
- CVN766 for negative and cognitive symptoms of schizophrenia will advance to Phase 2 study in Q4 2023
- CVN293 for Amyotrophic Lateral Sclerosis will advance to Phase 1 study in Q3 2023
January 27, 2023
Cerevance Announces Publication in Organic Process Research and Development
Cerevance today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.
January 9, 2023
Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia
- CVN766 was well tolerated with no serious adverse events
- CVN766, which has >1000-fold selectivity for the orexin 1 receptor, was well tolerated and showed no evidence of somnolence
- Data supports once a day dosing of CVN766 in future studies
November 30, 2022
Cerevance to Present Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology
- Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform
- Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to neuroinflammation in neurodegenerative disease
- Data has been concurrently published in the peer-reviewed journal, Neuropharmacology
August 9, 2022
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
Cerevance today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.
April 19, 2022
Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
Cerevance today announced the appointment of Craig Thompson to chief executive officer. Mr. Thompson brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to the company.
March 31, 2022
Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
Cerevance today announced the completion of its Phase 2 clinical trial of CVN424, the company’s first-in-class, once-a-day, orally-delivered compound in development for the treatment of Parkinson’s disease.
January 25, 2022
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
September 8, 2021
Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors
Cerevance today announced the appointment of Mike Poole, M.D., FACP, to Cerevance’s Board of Directors.
February 1, 2021
Cerevance Appoints Carrie Ann Cook as Chief Business Officer
Cerevance, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer
February 1, 2021
Cerevance Appoints Naidong Ye, Ph.D. as Vice President and Head of Chemistry, Manufacturing and Controls
Cerevance today announced the appointment of Naidong Ye, Ph.D., a seasoned chemist with extensive pharmaceutical industry experience, as vice president and head of chemistry, manufacturing and controls (CMC).
December 8, 2020
Cerevance Appoints David Lubner to Board of Directors
Cerevance today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors.
November 16, 2020
Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
Cerevance today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS).
July 21, 2020
Cerevance Expands Series B Financing to $65 Million
Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April.
April 14, 2020
Cerevance Closes $45 Million Series B Financing
Cerevance has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s previous investors...
January 7, 2020
Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors
Dr. Brennan is currently president and chief executive officer of Synlogic, Inc. (Nasdaq:SYBX), a clinical stage biotechnology company applying synthetic biology to beneficial microbes to develop novel, living medicines.
December 17, 2019
Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders
Cerevance has formed a multi-year research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain GI disorders.
December 4, 2019
Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease
Cerevance, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a novel, non-dopaminergic target selectively expressed in an important class of neurons in the striatum.
June 3, 2019
Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor
Cerevance has appointed pharmaceutical industry veteran, James Summers, Ph.D., as a key scientific advisor to guide the company in its drug discovery and development efforts. Dr. Summers brings extensive experience in the discovery of...
April 30, 2019
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1 clinical trial of CVN424, the company’s first-in-class, orally-delivered compound in development for the treatment of Parkinson’s disease.
April 16, 2019
Cerevance Appoints Industry Veteran Roland Bürli, Ph.D. as Vice President of Drug Discovery
Roland Bürli, Ph.D. as Vice President of Drug Discovery brings expertise in preclinical drug discovery, specializing in medicinal and synthetic chemistry, with a proven track record from hit identification through lead optimization, having led efforts that discovered six pre-clinical candidate molecules, including a program now in Phase II.
March 5, 2019
Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as VP of Neuroscience
Dawson brings 25 years of career experience spearheading drug discovery and development across companies based in the United States, Japan and the United Kingdom. Most recently, he served as Vice President of CNS drug development at Astex Pharmaceuticals, where he established and developed their global neuroscience research strategy.
October 9, 2018
Cerevance Appoints Ted Hibben as Chief Business Officer
A twenty-year biotechnology industry veteran, Mr. Hibben has formed over $2 billion in platform and product-based R&D collaborations. Prior to joining Cerevance, Mr. Hibben served as Chief Business Officer at Catabasis where he led partnering activities.
September 25, 2018
Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease
Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease.
February 21, 2018
Cerevance Kicks Off 2018 with Additional $10 Million of Infusions
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has received an additional equity investment as well as a non-dilutive cash payment in the first six weeks of 2018 totaling more than $10 million.
November 27, 2017
Cerevance Appoints David H. Margolin, M.D., Ph.D., as Senior Vice President of Clinical and Translational Medicine
Prior to joining Cerevance, Dr. Margolin served in several leadership roles at Sanofi-Genzyme over a 14-year period. There, he leveraged his expertise in designing and leading translational medicine initiatives as well as clinical trials from phase 1 to phase 4 across various neurologic and rare disease indications...
October 24, 2017
Trailblazer in Molecular Genetics and Neuroscience, Jeremy Nathans, M.D., Ph.D., to Advise Cerevance
Dr. Nathans is Professor of Molecular Biology and Genetics, Neuroscience and Ophthalmology at the Johns Hopkins University School of Medicine in Baltimore, Maryland, where his research focuses on molecular mechanisms of visual system development, function, and disease. He is also an Investigator in the Howard Hughes Medical Institute.
October 17, 2017
Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University
Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue
October 12, 2017
Harvard’s Rudolph Tanzi, Ph.D., a Leader in Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board
Cerevance, a drug discovery and development company focused on brain diseases, today announced that Rudolph Tanzi, Ph.D., has joined the company as a senior-level scientific advisor.
October 5, 2017
Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., to Advise Cerevance
Cerevance, a drug discovery and development company, today announced that Robert Malenka, M.D., Ph.D., has joined the company as a senior-level scientific advisor. Dr. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences at Stanford University.
May 3, 2017
Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia
The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance.
December 2, 2016
Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
- Takeda and Lightstone Ventures Participate in Series A Financing
- Former Takeda Cambridge UK employees, CNS programs moved to create turn-key discovery capabilities
Current
September 23, 2024
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
June 18, 2024
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
May 20, 2024
Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention
May 9, 2024
Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
April 29, 2024
Cerevance to Present at RBC Capital Markets 2024 Global Healthcare Conference
April 29, 2024
Cerevance to Participate at Wells Fargo Virtual Private Biotech Symposium
April 17, 2024
Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England
April 2, 2024
Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference
March 13, 2024
Cerevance Announces Presentation at Alzheimer’s Research UK Conference
February 27, 2024
Cerevance Announces Presentation at AD/PD™ 2024 International Conference
February 22, 2024
Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference
December 5, 2023
Cerevance to Participate in Fireside Chat at the 2023 RBC Capital Markets Healthcare Private Company Virtual Conference
November 28, 2023
Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
November 7, 2023
Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting
November 1, 2023
Cerevance to Participate in the Truist Securities BioPharma Symposium
October 25, 2023
Cerevance to Participate at the Wells Fargo 2023 Private Biotech Symposium
October 18, 2023
Cerevance to Participate at the Leerink Biopharma Private Company Connect
October 10, 2023
Cerevance to Participate at the 3rd Annual Needham Biotech Private Company Forum. Company management will host one-on-one meetings during the conference.
October 4, 2023
Cerevance to Participate at the 2023 Life Sciences Private Company Showcase
October 2, 2023
Cerevance to Present at the 36th European College of Neuropsychopharmacology Congress
September 5, 2023
Cerevance to Present During the 6th Annual LSX World Congress USA
August 31, 2023
22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium
July 10, 2023
Alzheimers Association International Conference
June 28, 2023
XVI European Meeting on Glial Cells in Health and Disease
June 26, 2023
Gordon Research Conference
May 16, 2023
Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP)
May 9, 2023
Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development
May 8, 2023
2023 RBC Capital Markets Global Healthcare Conference
April 13, 2023
BNA International Festival of Neuroscience
April 10, 2023
Needham Healthcare Conference
March 27, 2023
Chief Medical Officer Summit 360˚
March 21, 2023
Two Medicinal Chemistry Conferences
March 20, 2023
AD/PD™ 2023 International Conference
March 7, 2023
Alzheimer’s Research UK Conference 2023
January 24, 2023
SVB Global Biopharma Conference
December 7, 2022
Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
November 30, 2022
Biology and Therapeutics Conference
June 16, 2022
5th Annual LSX World Congress USA
June 8, 2022
2022 BIO International Convention
The ASCEND Parkinson’s Disease Clinical Research Study
The ASCEND clinical study is evaluating whether CVN424, an investigational drug, is safe and effective in improving the motor and non-motor symptoms of Parkinson’s disease.
